Insilico Medicine
corporateWebsite
field
Medicine
sub field
AI / MLDrug DiscoveryLongevityOncology
approach
Applied
Fund rating
0.0 / 35
0 published reviews
No per-dimension scores yet.
Published reviews
About
Direct fit with OpenDrugs' AI-native longevity and drug-discovery focus. The evidence explicitly ties Insilico to aging biomarkers, longevity targets, and an AI foundation model for longevity science, which aligns with OpenDrugs' provenance-backed compound knowledgebase and combination discovery goals.